N-((1R,3S)-3-((2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-yl)amino)cyclohexyl)-1-methyl-1H-imidazole-5-carboxamide

ID: ALA3317990

Chembl Id: CHEMBL3317990

PubChem CID: 118708559

Max Phase: Preclinical

Molecular Formula: C22H22ClFN8O

Molecular Weight: 468.92

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  Cn1cncc1C(=O)N[C@@H]1CCC[C@H](Nc2nc(-c3c[nH]c4ncc(Cl)cc34)ncc2F)C1

Standard InChI:  InChI=1S/C22H22ClFN8O/c1-32-11-25-10-18(32)22(33)30-14-4-2-3-13(6-14)29-21-17(24)9-28-20(31-21)16-8-27-19-15(16)5-12(23)7-26-19/h5,7-11,13-14H,2-4,6H2,1H3,(H,26,27)(H,30,33)(H,28,29,31)/t13-,14+/m0/s1

Standard InChI Key:  HVPVWIOMBFSELN-UONOGXRCSA-N

Alternative Forms

  1. Parent:

    ALA3317990

    ---

Associated Targets(non-human)

Influenza A virus (11224 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PB2 Polymerase basic protein 2 (86 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 468.92Molecular Weight (Monoisotopic): 468.1589AlogP: 3.70#Rotatable Bonds: 5
Polar Surface Area: 113.41Molecular Species: NEUTRALHBA: 7HBD: 3
#RO5 Violations: HBA (Lipinski): 9HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: 12.65CX Basic pKa: 4.92CX LogP: 2.25CX LogD: 2.25
Aromatic Rings: 4Heavy Atoms: 33QED Weighted: 0.41Np Likeness Score: -1.23

References

1. Clark MP, Ledeboer MW, Davies I, Byrn RA, Jones SM, Perola E, Tsai A, Jacobs M, Nti-Addae K, Bandarage UK, Boyd MJ, Bethiel RS, Court JJ, Deng H, Duffy JP, Dorsch WA, Farmer LJ, Gao H, Gu W, Jackson K, Jacobs DH, Kennedy JM, Ledford B, Liang J, Maltais F, Murcko M, Wang T, Wannamaker MW, Bennett HB, Leeman JR, McNeil C, Taylor WP, Memmott C, Jiang M, Rijnbrand R, Bral C, Germann U, Nezami A, Zhang Y, Salituro FG, Bennani YL, Charifson PS..  (2014)  Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2.,  57  (15): [PMID:25019388] [10.1021/jm5007275]

Source